Sector | Healthcare | Compare with Sector peers |
Industry | Pharmaceuticals & Drugs | Compare with Industry peers |
Website | http://www.vineetlabs.co.in | |
Market Cap | 45.45 Cr. | |
Enterprise Value(EV) | 84.96 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 2.87 | Trailing Twelve Months Ending 2023-12 |
Price-Earning Ratio (PE) | 17.15 | Trailing Twelve Months Ending 2023-12 |
Industry PE | 41.54 | Trailing Twelve Months Ending 2023-12 |
Book Value / Share | 35.56 | Trailing Twelve Months Ending 2023-12 |
Price to Book Value | 1.39 | Calculated using Price: 49.30 |
Dividend Yield | 0.00 | Period Ending 2023-03 |
No. of Shares Subscribed | 0.92 Cr. | 9,219,008 Shares |
FaceValue | 10 | |
About Vineet Laboratories Ltd. | ||
The company is engaged in the business of Drug Intermediates & Bulk Dugs. |
1 Day |
|
+2.32% |
1 Week |
|
+1.86% |
1 Month |
|
-15.48% |
3 Month |
|
-29.27% |
6 Month |
|
-5.16% |
1 Year |
|
+17.10% |
2 Year |
|
-10.36% |
5 Year |
|
|
10 Year |
|
6 years | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | 0 | 0 | -2.87 | 13.18 | 22.19 | 3.74 | |
Return on Capital Employed (%) | 0 | 0 | -2.87 | 34.06 | 23.14 | 8.69 | |
Return on Assets (%) | 0 | 0 | -2.72 | 3.26 | 5.49 | 1.01 |
Particulars | 7 years | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 0 | 0 | 0 | 27 | 33 | 34 | 35 | |
Non Curr. Liab. | 7 | 5 | 8 | 7 | ||||
Curr. Liab. | 0 | 0 | 75 | 95 | 75 | 80 | ||
Minority Int. | ||||||||
Equity & Liab. | 0 | 0 | 0 | 109 | 133 | 116 | 122 | |
Non Curr. Assets | 22 | 31 | 28 | 28 | ||||
Curr. Assets | 0 | 0 | 0 | 86 | 103 | 87 | 94 | |
Misc. Exp. not W/O | 0 | 0 | ||||||
Total Assets | 0 | 0 | 0 | 109 | 133 | 116 | 122 |
Particulars | 7 years | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
Net Sales | 243 | 191 | 212 | 171 | ||||
Other Income | 0 | 0 | 0 | 0 | ||||
Total Income | 244 | 191 | 212 | 171 | ||||
Total Expenditure | 0 | -235 | -178 | -205 | -161 | |||
PBIDT | 0 | 9 | 13 | 8 | 10 | |||
Interest | -3 | -2 | -3 | -3 | ||||
Depreciation | -2 | -2 | -2 | -2 | ||||
Taxation | -2 | -3 | -1 | -1 | ||||
Exceptional Items | ||||||||
PAT | 0 | 2 | 7 | 1 | 3 | |||
Adjusted EPS | 0 | 2 | 7 | 1 | 3 |
Particulars | 6 years | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 27 | 8 | -10 | ||||
Cash Fr. Inv. | -8 | -4 | -7 | ||||
Cash Fr. Finan. | 19 | 12 | 0 | ||||
Net Change | 38 | 16 | -16 | ||||
Cash & Cash Eqvt | 38 | 17 | 1 |
Fri, 29 Mar 2024
Closure of Trading Window The trading window for dealing in the securities of the Company will remain closed from April 1 2024 till 48 hours after the announcement of Standalone Audited Financials Results for the Fourth Quarter and the Financial Year ended on March 31 2024. for all the designated persons their immediate relatives and all the connected persons covered under the code.The Company has ensured freezing of PAN of all the designated persons and their immediate relatives during the period of trading window closure. |
Wed, 14 Feb 2024
Announcement under Regulation 30 (LODR)-Newspaper Publication Newspaper Publication of the Unaudited Financial Results for the Third Quarter and Nine months ended on December 31 2023. |
Mon, 12 Feb 2024
Board Meeting Outcome for Outcome For The Board Meeting Held On Monday February 12 2024 As Required Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 The Board of Directors in its meeting held today i.e. on February 12 2024 has considered and approved the unaudited Financial results of the Company for the Third Quarter and the Nine months ended on December 31 2023 |
Thu, 28 Mar 2024 |
Close Below Last Month Low |
Making Lower Lows for 2 Days |
High Decrease in 1 Month |
High Decrease in 3 Months |
Bullish Harami Cross |